Clinical Trials Logo

CIDP clinical trials

View clinical trials related to CIDP.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05614128 Recruiting - CIDP Clinical Trials

Validation of Cutaneous Nerve Demyelination in Diagnosis and Treatment of CIDP

Start date: February 28, 2023
Phase:
Study type: Observational

The goal of this observational study is to learn about chronic inflammatory demyelinating polyneuropathy. The main question the investigators would like to answer is 1) can skin biopsy identify demyelination better than nerve conduction studies (electrical tests of the nerves)? and 2) how do nerves improve after treatment in CIDP? Participants will be asked to undergo skin biopsy of the finger at baseline and at 3 months and 6 months after treatment with IVIG (which is the FDA approved treatment for CIDP).

NCT ID: NCT05584631 Recruiting - Clinical trials for Chronic Inflammatory Demyelinating Polyneuropathy

IVIG vs SCIG in CIDP

Start date: September 11, 2022
Phase: Phase 1
Study type: Interventional

Current dosing practices for immunoglobulin G (IgG) may be inadequate in extreme body weight. The current study will evaluate the influence of body composition on intravenous and subcutaneous administration of immunoglobulin G in patients.

NCT ID: NCT05004493 Recruiting - Clinical trials for Antibody-mediated Rejection

Biorepository and Registry for Plasma Exchange Patients

Start date: July 28, 2021
Phase:
Study type: Observational [Patient Registry]

Patients who have immune mediated diseases commonly undergo plasma exchange (PLEX) procedures to remove pathological substances, typically believed to be antibodies. At our facility about 400 of these procedures are performed annually on 40-60 different patients. These procedures are considered within the standard of care for these patients and are covered by insurance. This study will not influence the treatment plan for subjects who participate in this study. The goal of the study is to collect and cryopreserve blood biospecimens (plasma, serum, PBMCs) for current and future studies. Any patient undergoing plasma exchange procedures will be eligible for the study. Patients or the legally authorized representative (LAR) will be consented for the study as soon as feasible after the are referred to DeGowin for plasma exchange. The immediate objective of the study is to examine antibody levels (IgG/IgM) and BAFF levels in the blood of these patients over the course of the plasma exchange treatments. Specimens and clinical data will be collected such that other immune factors that may regulate B cell survival, proliferation and antibody secretion can be studied. Another goal of the study is to isolate and cryopreserve PBMCs at different points during the patient's treatment. This would allow the study of immune cells that may mediate these diseases. The study will also follow pathological antibodies over time in these patients so biospecimens can be obtained even after the completion of their course of plasma exchange treatments. The collection of biospecimens and clinical information from these subjects will help us understand the impact of plasma exchange on both normal and pathological immune factors in a variety of patients undergoing these procedures.

NCT ID: NCT04881682 Recruiting - CIDP Clinical Trials

Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

IVITOC
Start date: May 1, 2023
Phase: Phase 2
Study type: Interventional

This is a randomized controlled study evaluating safety and efficacy of repeated immunoadsorption versus immunoglobulins in steroid-refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

NCT ID: NCT04249752 Recruiting - Clinical trials for Guillain-Barre Syndrome

Biomarkers in Polyradiculoneuropathies

BIP
Start date: January 1, 2020
Phase:
Study type: Observational

The nodes of Ranvier contain ion channels that enable the rapid propagation of the nerve impulse. Cell adhesion molecules and glycolipids play an important role in the formation of the nodes of Ranvier. Antibodies against glycolipids are detected in half of patients with Guillain-Barré syndrome, an acute inflammatory neuropathy affecting peripheral nerve. The investigators found that antibodies target cell adhesion molecules at nodes of Ranvier in 10% of patients with chronic inflammatory demyelinating neuropathy (CIDP), another disabling neuromuscular disease affecting peripheral nerves. In the majority of patients with GBS or CIDP, the mechanisms responsible for the neuromuscular disorders are unknown. Our goals are to identify novel targets of antibodies in patients, this in order to find novel bio-markers and to better understand the physiopathology of inflammatory neuropathies. This work will help patient diagnosis and treatment orientation.

NCT ID: NCT03801135 Recruiting - Clinical trials for Guillain-Barre Syndrome

Changes in Haemostasis After Therapeutic Plasmapheresis With Citrate Anticoagulation

Start date: October 3, 2018
Phase: N/A
Study type: Interventional

Plasma exchange procedures remove procoagulant and anticoagulant factors. Every procedure increases the risk of bleeding and repeated procedures increase the risk of bleeding mostly because lower fibrinogen levels. The aim of study is to define coagulation status of patient after plasmapheresis with different laboratory tests and to investigate the possibility of fibrinogen concentrate replacement for the correction of induced coagulation disorder.